Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.4352W HIGH $15.79
Volume
595.44 K
Value Traded
8.04 M
Short % Float
4.72%
-5.21%Week
-1.89%1 Month
+10.15%3 Month
+92.04%6 Month
+4.04%5 Year
+402%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.26 B
EPS (TTM)
-0.66
P/E Ratio
-
Ent. Value
817.73 M
Total Shares
90.27 M
Float Shares
73.72 M
Insiders
20.28%
Institutions
9.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DRTS Catalyst Timeline
Dated clinical, regulatory and corporate events for Alpha Tau Medical Ltd.
Past FDA Catalysts and PDUFA Decisions
How DRTS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Alpha Tau Medical Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DRTS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Alpha DaRT Breakthrough | pancreatic ductal adenocarcinoma | Phase 1/2 | 2026-06-01 | median overall survival (mOS) of 11.2 months in metastatic disease; median overall survival (mOS) of 11.1 months in locally advanced disease; historical data shows ~4 - 6 months for metastatic patients; historical data shows ~9 months for locally advanced patients; median overall survival of 17.0 months in metastatic disease for patients who had received one prior line of chemotherapy; median overall survival of 13.8 months in locally advanced disease for patients who had received one prior line of chemotherapy; treatment-associated adverse events reported in 36% of subjects; Grade 3 events in 9%; no treatment-related deaths; no chronic toxicityRead More | Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, miRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Levy RaphiOfficer (Chief Financial Officer) | Option | 2,871 93,051 held | $2.98 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DRTS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DRTS for Q2 2026. | ||||
DRTS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DRTS ranks across every disease it competes in
Competitive Position is a premium feature
See how DRTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDRTS News
DRTSOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Pharmaceuticals has announced its inclusion in the Russell 2000 and 3000 indexes, which is expected to enhance its visibility and shareholder base. The company has also significantly repaid its Scilex loan, recovering approximately $118 million of the $99.5 million loan. Additionally, Oramed's balance sheet is strong, with total cash and assets around $270 million as of March 31, 2026.
Read more →DRTSAlpha Tau Receives FDA Clearance to Complete
Alpha Tau Medical has received FDA clearance to resume patient enrollment in its REGAIN trial for recurrent glioblastoma, following positive interim results showing 100% local disease control among initial patients. The trial will now include two additional U.S. academic cancer centers, which will broaden geographic access and expertise. The interim results also revealed a 67% complete response rate, highlighting the potential of Alpha DaRT as a transformative treatment option. This regulatory success marks a continuation of the company's promising journey in glioblastoma treatment development.
Read more →DRTS▲ +18.5%on this news
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients
Alpha Tau Medical Ltd. and Tolmar International Ltd. have announced a strategic partnership to commercialize Alpha DaRT therapy for prostate cancer in the United States. Under this agreement, Tolmar will have exclusive rights to market the therapy, supported by a $15 million manufacturing investment and a $20 million equity infusion. The collaboration emphasizes the importance of developing alternatives for prostate cancer treatment and has the potential to significantly impact patient care. Additionally, there is an option for Tolmar to expand commercialization into bladder cancer, subject to meeting certain criteria.
Read more →DRTS▼ -10.8%on this newsshared move
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Alpha Tau Medical announced promising overall survival results for its Alpha DaRT treatment for pancreatic cancer, presented at the 2026 ASCO Annual Meeting. A pooled analysis from three Phase I/II studies showed significant median overall survival improvements in comparison to historical chemotherapy data. The treatment demonstrated a favorable safety profile with no chronic toxicity or treatment-related deaths reported. Following these results, Alpha Tau aims to continue its clinical trials for Alpha DaRT as a complementary therapy alongside front-line chemotherapy.
Read more →DRTSAlpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Medical Ltd. reported its first quarter 2026 financial results, highlighting significant progress in its clinical trials, including 100% local disease control in the REGAIN trial for recurrent glioblastoma and 67% complete response rate. The company also announced completion of patient enrollment in its pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma. Despite a net loss of $22.9 million, Alpha Tau maintains a solid cash balance of $80.2 million to support its ongoing research and development efforts. The growing recognition of the company's clinical data at major conferences further underscores its potential in oncology.
Read more →DRTSAlpha Tau to Participate in May Investor Conferences
Alpha Tau Medical Ltd. has announced that its CFO, Raphi Levy, will participate in several investor conferences throughout May 2026. These conferences include the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Rothschild & Co Redburn Radiopharma Conference, among others. Mr. Levy will be available for one-on-one meetings at all events, suggesting a proactive approach to investor relations. The participation indicates the company's ongoing efforts to engage with potential investors and promote its innovative alpha-radiation cancer therapy, Alpha DaRT.
Read more →DRTS▲ +21.5%on this news
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
Alpha Tau Medical announced promising interim results from its U.S. trial of Alpha DaRT for recurrent glioblastoma, showing 100% local disease control and a 67% complete response rate among the first three patients treated. The trial, which aims to provide new treatment options for this challenging cancer, reported a favorable safety profile with only one serious adverse event, now resolved. A conference call is scheduled to discuss these findings further.
Read more →DRTS▲ +21.5%on this newsshared move
Revolutionary Alpha-Emitters Radiotherapy: Brain Tumors 1 2 This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested partie
Alpha Tau Medical Ltd. has presented information on its Alpha DaRT technology, which employs alpha-emitting radiotherapy for treating brain tumors and other cancers. The presentation outlines the mechanism of action and discusses upcoming milestones and clinical trials. However, it also emphasizes the significant risks and uncertainties in clinical development and regulatory approval. The company disclaims liability for information reliability, leaving potential investors cautious about making decisions based on this information.
Read more →DRTS▲ +8.4%on this news· ran to +32% by day 1shared move
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT to Treat Recurrent Cutaneous
Alpha Tau Medical Ltd. has successfully completed patient enrollment in its ReSTART pivotal trial, assessing the Alpha DaRT treatment for recurrent cutaneous squamous cell carcinoma (cSCC). This milestone is significant in the company's aim for FDA pre-market approval, leveraging a robust backdrop of data from prior studies in various countries. With 88 patients enrolled, the study will now advance to follow-up phases to evaluate key efficacy and safety endpoints. The trial is notable for addressing significant unmet needs in patients whose cancer has returned after conventional treatment methods have failed.
Read more →DRTS▲ +8.4%on this news· ran to +32% by day 1shared move
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Alpha Tau Medical Ltd. announced plans to host a conference call on May 11, 2026, to discuss interim clinical results from the first three patients treated for recurrent glioblastoma as part of its REGAIN trial. This innovative approach utilizes the company's Alpha DaRT technology, which delivers targeted alpha-radiation to tumors. The trial aims to evaluate treatment feasibility and safety specifically for patients not eligible for surgical resection. The study is part of a push for new therapeutic options in the challenging landscape of brain cancer treatment.
Read more →DRTSAlpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute
Alpha Tau Medical Ltd. has successfully treated the first pancreatic cancer patient in Italy using its Alpha DaRT therapy at the University of Verona's Pancreas Institute. This marks a significant milestone as it is the first protocol worldwide to allow both endoscopic ultrasound and percutaneous delivery methods. The study aims to provide new treatment options for patients with locally advanced pancreatic cancer, reflecting Alpha Tau's commitment to expanding its global clinical program.
Read more →DRTSAlpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT Head and Neck Cancer Combination
Alpha Tau Medical Ltd. has announced that an abstract showcasing the results of their innovative therapy, Alpha DaRT, in combination with pembrolizumab has been accepted for podium presentation at the AHNS 12th International Conference on Head and Neck Cancer scheduled for July 2026. This study focuses on elderly patients suffering from advanced head and neck cancers, a population with notably limited treatment options. The combination therapy is expected to enhance immune activation without increasing treatment toxicity, presenting a promising advancement in cancer care. The selection for podium presentation underscores the significance of their findings in the field of oncology.
Read more →DRTS▼ -11.8%on this newsshared move
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau Medical Ltd. announced a 100% local disease control rate in pancreatic cancer patients treated with Alpha DaRT in two first-in-human trials. The results, presented at DDW 2026, showed a favorable safety profile with minimal adverse events. The treatment is designed for easy integration into standard procedures, highlighting its potential in oncology.
Read more →DRTSAlpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
Alpha Tau Medical announced that its abstract on Alpha DaRT for pancreatic cancer has been accepted at the ASCO Annual Meeting. This pooled analysis includes data from 58 patients across three studies, showcasing promising safety and efficacy. The acceptance reflects increasing recognition of Alpha Tau's clinical program and its innovative approach to treating pancreatic cancer.
Read more →DRTSAlpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane (Nab-Paclitaxel)
Alpha Tau Medical Ltd. has received FDA approval for an Investigational Device Exemption (IDE) supplement, which allows the expansion of its IMPACT study. This enhancement will enable the inclusion of additional patients receiving gemcitabine and nab-paclitaxel, increasing the trial size from 30 to 40 patients. The study focuses on assessing the safety and efficacy of Alpha DaRT in combination with chemotherapy for newly diagnosed pancreatic cancer patients. Alpha Tau aims to meet the pressing medical needs surrounding pancreatic cancer treatment through this clinical program.
Read more →DRTSAlpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
Alpha Tau Medical has successfully treated the first patient in the ACAPELLA trial, which evaluates the Alpha DaRT therapy combined with capecitabine for inoperable locally advanced pancreatic cancer. This trial aims to provide a treatment path for patients who have completed first-line chemotherapy but lack further options. The procedure was performed at CHU Grenoble Alpes, marking a significant step in Alpha Tau's clinical expansion in Europe.
Read more →DRTS▲ +7.9%on this news
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
Alpha Tau Medical Ltd. has announced that its abstract on Alpha DaRT for pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026. This marks a significant milestone as it is the first time results of Alpha DaRT in pancreatic cancer patients will be presented at a major gastroenterology conference. The presentation will be led by Dr. Harold Jacob and will highlight the feasibility, safety, and tumor control of the treatment.
Read more →DRTSAlpha Tau to Present at Sidoti March Virtual Small Cap Conference
Alpha Tau Medical Ltd. (Nasdaq: DRTS) has announced that its CFO, Raphi Levy, will present at the Sidoti Virtual Small Cap Conference, scheduled for March 18-19, 2026. The event will highlight the company's innovative alpha-radiation cancer therapy, Alpha DaRT, which aims to treat solid tumors while sparing surrounding healthy tissue. Attendees will have the opportunity to schedule one-on-one investor meetings with Mr. Levy, further facilitating discussions about the company's developments.
Read more →DRTSAlpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau Medical Ltd. announced its full year 2025 financial results and a corporate update, highlighting significant recent achievements including the receipt of marketing approval in Japan and the approval of five clinical trials in the U.S. The company reported a net loss of $42.6 million, which was higher than the previous year's loss, primarily due to rising research and development costs. They noted a strong cash position of $76.9 million, which supports ongoing clinical advancements and preparations for commercialization. Upcoming milestones include progress in multiple pivotal trials in the U.S.
Read more →DRTSAlpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
Alpha Tau Medical has received marketing approval from Japan's Ministry of Health for its Alpha DaRT therapy, marking the first authorization outside Israel. This approval initiates a post-market surveillance study to evaluate the therapy's safety and effectiveness in real-world settings. The company aims to collaborate with Japanese clinicians to generate further clinical data and explore reimbursement strategies.
Read more →About Alpha Tau Medical Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next DRTS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime